SciELO - Scientific Electronic Library Online

vol.31 número2Anatomía Macroscópica del Estómago del Ciervo Elaphus barbarusLa Odontología Forense como un Ejercicio de Morfología en la Investigación Medicolegal de la Muerte índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados


International Journal of Morphology

versión On-line ISSN 0717-9502


ROSAS C, Carlos et al. Celecoxib Effect in a Multiresistant Variant of the TA3 Tumor: A Histological Description. Int. J. Morphol. [online]. 2013, vol.31, n.2, pp.392-398. ISSN 0717-9502.

In the study of cancer diverse cellular lines are in use, each with its own characteristics. One of these tumor lines is the TA3 tumor variant, multi resistant to drugs. Although diverse studies exist in reference to this tumor line, there are no detailed morphological descriptions of this one, nor those that observe the effect of Celecoxib, a COX-2 tissue inhibitor. We used 18 mice divided in 3 groups that received PBS inoculation; TA3 tumor cell inoculation; cell tumor inoculation + treatment with Celecoxib (1000ppm) respectively. The mice were sacrificed and histologically processed with H & E, PAS and Arteta stain. The study revealed that tumor showed a marked heterogeneity, some areas of necrosis and central and peripheral neovascularization. Furthermore, Celecoxib significantly reduced tumor invasion in the liver (p< 0.05). Other organs did not show significant differences when compared with the treated group. The results are similar to partial descriptions realized in the past and are comparable to other tumor lines. It is estimated that the route of medication administration is critical for result interpretation. These results are important in the discussion of other research where Celecoxib is used as an antiangiogenic drug and serves as base for future research within this tumor line.

Palabras clave : Tumor; Angiogenesis; Celecoxib.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons